Well aside from the failed clincal trials, GTX seems to have changed the company name and no longer has ostarine as a drug in their pipeline. I guess that means it will remain a research chem?
This month the "ostarine" company GTx merged with Oncternal. Oncternal does not list GTx-024 (ostarine) as one of their products. But, why would Oncternal merge with GTx if not to obtain the rights to ostarine? My guess is that they either intend to bring it to market (it was too expensive for GTx), or they intend to sell the rights.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.